利妥昔单抗治疗温抗体自身免疫性溶血性贫血的疗效评价  

Evaluation of rituximab in the treatment of warm-antibody autoimmune hemolytic anemia

作　　者：陆欣[1] 王海军[1] 赵丽云[1] 李玉伟[2] 王助衡[2] 

机构地区：[1]河北医科大学附属邢台市人民医院血液科,河北054001 [2]首都医科大学附属大兴医院重症医学科,北京102600

出　　处：《实用药物与临床》2015年第1期102-104,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的评价利妥昔单抗治疗温抗体自身免疫性溶血性贫血(WAIHA)的临床疗效。方法选择2012年1月10日至2013年12月30日在我院被诊断为WAIHA的160例患者为研究对象,随机分为试验组(80例)和对照组(80例)。试验组接受375 mg/m2利妥昔单抗,1次/周,连续4周,对照组接受同等体积的生理盐水进行治疗。随访12个月后进行数据统计分析。结果试验组的完全缓解率(65%)高于对照组(35%),1年复发率(10%)低于对照组(50%),两组比较差异有统计学意义(P<0.05)。结论利妥昔单抗治疗WAIHA可以提高患者的完全缓解率,降低患者的复发率。Objective To assess the efficacy of rituximab in the treatment of warm-antibody autoimmune hemolytic anemia（ WAIHA）. Methods A total of 160 WAIHA patients admitted to our hospital from June 2012 to December 2013 were randomly divided into experimental group（ n = 80） and control group（ n = 80）. Experimental group received rituximab at a dose of 375 mg / m2 once a week for 4 weeks,control group was given an equal volume of physiological saline. The efficacy of rituximab was analysed after 12 months followup. Results The complete response rate of experimental group（ 65%） was higher than that of control group（ 35%）,there was significant difference between the two groups（ P〈0. 05）. Furthermore,recurrence rate of experimental group（ 10%） was lower than that of control group（ 50%）,there was significant difference between the two groups（ P〈0. 05）. Conclusion Rituximab in the treatment of WAIHA can increase complete response rate and decrease the recurrence rate.

关 键 词：利妥昔单抗 温抗体自身免疫性溶血性贫血 抗体治疗 

分 类 号：R556[医药卫生—血液循环系统疾病]